This review evaluated the efficacy of triple-H (hypertension, hypervolaemia, haemodilution) therapy in reducing the occurrence of clinical vasospasm, delayed ischaemic neurological deficits, and death after subarachnoid haemorrhage. The authors' concluded appropriately that a lack of evidence combined with limitations in the design of included studies preclude evaluation of the effects of triple-H prevention or any recommendations regarding its use.
The authors assessed the internal validity of the primary studies using Jadad quality criteria. To assess external validity, they scored studies on the following: documentation of diagnosis of spontaneous, aneurysmal SAH; definition of start of triple-H prevention after SAH; definition of duration of triple-H prevention; target for therapy; target mentioned for controls; the duration of follow-up; and adverse events mentioned. Four reviewers independently assessed the internal validity of the included trials, with agreement reached by discussion in the case of discrepancy. The authors did not state how judgements of external validity were made.
Data extraction
Three reviewers independently extracted the data from the primary studies. Any discrepancies were resolved through discussion until a consensus was reached. Information were recorded on: patient characteristics, type and timing of aneurysm intervention; timing, regimen and monitoring of prophylactic therapy; type of clinical and/or neuroimaging follow-up; and any concomitant treatments during prevention therapy. Relative risk (RR) estimates of incidence data were calculated, together with 95% confidence intervals (CIs), for symptomatic vasospasm, DINDs and death.
Methods of synthesis
How were the studies combined? Where appropriate, the studies were combined using a fixed-effect model; where significant (P>0.1) statistical heterogeneity was detected, a random-effects model was substituted. Three outcomes of the review (vasospasm, DINDs and death) were combined quantitatively in this way.
How were differences between studies investigated?
The authors implied that formal statistical tests were used to assess heterogeneity. The authors also used sensitivity analyses to investigate the impact of randomisation or treatment allocation concealment on the pooled RRs of symptomatic vasospasm, DINDs and death. Tabular presentation of participant and intervention characteristics and validity indicators allowed further investigation of between-study differences.
Results of the review
Four studies (n=488) were included in the review: two randomised controlled trials (n=112), and two cohort studies with historical and parallel designs (n=348 and n=28, respectively).
The included studies scored 0, 0, 1 and 2 according to the Jadad quality criteria, out of a maximum score of 5. For external validity, the studies were allocated scores of 2, 3, 3 and 6 out of a potential maximum score of 7. The authors of one randomised controlled trial conducted an intention-to-treat analysis.
Angiographically confirmed vasospasm (1 study): three cases (20%) were reported in the treatment group and nine cases (60%) in the control group.
Symptomatic vasospasm (4 studies): triple-H therapy conferred a protective effect against symptomatic vasospasm, with a combined RR of 0.45 (fixed-effect model, 95% CI: 0.32, 0.65). Trials without allocation concealment gave a slightly bigger treatment effect, with a RR of 0.4 (fixed-effect model, 95% CI: 0.26, 0.61).
DINDs (3 studies): the RR was 0.54 (95% CI: 0.2, 1.49). In the trial with allocation concealment, the RR was 1.75 (95% CI: 0.55, 5.53).
Medical complications (2 studies): one case of left ventricular failure (2%) was reported in the treatment group; two cases of hyponatraemia in each group were reported; and cerebral oedema was detected in 15% of those in the treatment group and 17% of those in the control group. Another trial reported re-bleeding in 13% of those who received preventive therapy compared with 18% of those who did not.
